Author:
Campbell Kristen R.,Martins Rui,Davis Scott,Juarez-Colunga Elizabeth
Abstract
Abstract
Background
Tacrolimus is given post-kidney transplant to suppress the immune system, and the amount of drug in the body is measured frequently. Higher variability over time may be indicative of poor drug adherence, leading to more adverse events. It is important to account for the variation in Tacrolimus, not just the average change over time.
Methods
Using data from the University of Colorado, we compare methods of assessing how the variability in Tacrolimus influences the hazard of de novo Donor Specific Antibodies (dnDSA), an early warning sign of graft failure. We compare multiple joint models in terms of fit and predictive ability. We explain that the models that account for the individual-specific variability over time have the best predictive performance. These models allowed each patient to have an individual-specific random error term in the longitudinal Tacrolimus model, and linked this to the hazard of dnDSA model.
Results
The hazard for the variance and coefficient of variation (CV) loading parameter were greater than 1, indicating that higher variability of Tacrolimus had a higher hazard of dnDSA. Introducing the individual-specific variability improved the fit, leading to more accurate predictions about the individual-specific time-to-dnDSA.
Conclusions
We showed that the individual’s variability in Tacrolimus is an important metric in predicting long-term adverse events in kidney transplantation. This is an important step in personalizing the dosage of TAC post-transplant to improve outcomes post-transplant.
Publisher
Springer Science and Business Media LLC
Subject
Health Informatics,Epidemiology
Reference26 articles.
1. Hart A, Smith J, Skeans M, Gustafson S, Stewart D, Cherikh W, Wainright J, Kucheryavaya A, Woodbury M, Snyder J, et al. OPTN/SRTR 2015 annual data report: kidney. Am J Transplant. 2017; 17(S1):21–116.
2. Sellares J, de Freitas D, Mengel M, Reeve J, Einecke G, Sis B. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2011; 2(12):388–99.
3. Matas A, Smith J, Skeans M, Thompson B, Gustafson S, Schnitzler M, Stewart D, Cherikh W, Wainright J, Snyder J, et al. OPTN/SRTR 2012 annual data report: kidney. Am J Transplant. 2014; 14(S1):11–44.
4. Campbell KR, Juarez-Colunga E, Grunwald GK, Cooper J, Davis S, Gralla J. Comparison of a time-varying covariate model and a joint model of time-to-event outcomes in the presence of measurement error and interval censoring: application to kidney transplantation. BMC Med Res Methodol. 2019; 19(1):130.
5. Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, Goldberg A, Ho J, Karpinski M, Pochinco D, et al. Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development. J Am Soc Nephrol. 2017; 28(11):3353–62.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献